Rapid Readout: Routine Clinical Practice Use of IRd in Patients With Relapsed/Refractory Multiple Myeloma (The INSURE Study)
Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.
Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma
Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.
Dr. Lentzsch on the Utility of Cellular Therapies in Multiple Myeloma
Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.
Novel Therapies Under Study for Triple-Class Refractory Multiple Myeloma
Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.
Addressing Unmet Needs for Triple-Class Refractory Multiple Myeloma
Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.
Individualizing Therapy for Triple-Class Refractory Myeloma
Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.
Single-Agent Belantamab Mafodotin for Triple-Class Refractory Multiple Myeloma
An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.
Melflufen and Dexamethasone for Triple-Class Refractory Multiple Myeloma
The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.
Selinexor With Backbone Therapy for Triple-Class Refractory Multiple Myeloma
Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.
Establishing a Treatment Plan for Triple-Class Refractory Myeloma
Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.
Assessing and Managing Relapsed/Refractory Myeloma
Strategies for patient assessment and treatment selection in patients with relapsed/refractory multiple myeloma.
Reacting to Relapsed/Refractory Myeloma in the Clinic
Criteria for diagnosis and risk stratification in patients with relapsed/refractory multiple myeloma.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512